69 results
8-K
EX-99.1
AKBA
Akebia Therapeutics Inc.
9 May 24
Akebia Therapeutics Reports First Quarter 2024 Financial Results
7:03am
data to identify additional areas of potential benefits to patients; Akebia’s expectations with respect to engagement with the FDA on label expansion
8-K
EX-99.1
AKBA
Akebia Therapeutics Inc.
26 Sep 23
Akebia Announces Approval of Vafseo® (vadadustat) in Australia and Provides Commercial Update
4:47pm
, Key Accounts, reporting to Bennett Smith, Senior Vice President, Commercial, to lead customer engagement. Mr. Ray has a track record of successful … , a core value that is integral to successful customer engagement. I believe Graham can enable the company to maximize the value of Auryxia both
8-K
EX-99.1
cz5979p
30 May 23
Regulation FD Disclosure
7:34am